Nuformix (NFX) Stock Overview
Together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
NFX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Nuformix plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0019 |
| 52 Week High | UK£0.0056 |
| 52 Week Low | UK£0.0007 |
| Beta | 1.41 |
| 1 Month Change | -21.28% |
| 3 Month Change | -23.24% |
| 1 Year Change | 94.74% |
| 3 Year Change | -43.08% |
| 5 Year Change | -92.13% |
| Change since IPO | -95.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| NFX | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -9.8% | -3.1% | -3.5% |
| 1Y | 94.7% | 17.6% | 14.7% |
Return vs Industry: NFX exceeded the UK Pharmaceuticals industry which returned 17.6% over the past year.
Return vs Market: NFX exceeded the UK Market which returned 14.7% over the past year.
Price Volatility
| NFX volatility | |
|---|---|
| NFX Average Weekly Movement | 18.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.9% |
Stable Share Price: NFX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: NFX's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 3 | n/a | www.nuformix.com |
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd.
Nuformix plc Fundamentals Summary
| NFX fundamental statistics | |
|---|---|
| Market cap | UK£4.83m |
| Earnings (TTM) | -UK£652.59k |
| Revenue (TTM) | n/a |
Is NFX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NFX income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£652.59k |
| Earnings | -UK£652.59k |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00025 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NFX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/22 08:02 |
| End of Day Share Price | 2026/03/20 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nuformix plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Davison | Allenby Capital Limited |